RedHill Biopharma (RDHL) Current Leases (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Current Leases for 3 consecutive years, with $353000.0 as the latest value for Q4 2024.

  • Quarterly Current Leases fell 50.84% to $353000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $353000.0 through Dec 2024, down 50.84% year-over-year, with the annual reading at $353000.0 for FY2024, 50.84% down from the prior year.
  • Current Leases for Q4 2024 was $353000.0 at RedHill Biopharma, down from $718000.0 in the prior quarter.
  • The five-year high for Current Leases was $1.0 million in Q4 2022, with the low at $353000.0 in Q4 2024.
  • Average Current Leases over 3 years is $701000.0, with a median of $718000.0 recorded in 2023.
  • The sharpest move saw Current Leases tumbled 30.43% in 2023, then crashed 50.84% in 2024.
  • Over 3 years, Current Leases stood at $1.0 million in 2022, then crashed by 30.43% to $718000.0 in 2023, then plummeted by 50.84% to $353000.0 in 2024.
  • According to Business Quant data, Current Leases over the past three periods came in at $353000.0, $718000.0, and $1.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.